Skip to main content

Table 2 Oncologic features of the patients

From: Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy

Variable

Percentage (%)

Patient (n)

50

Gleason score (n, %)

 6

3 (6%)

 7

15 (30%)

 8

25 (50%)

 9

7 (14%)

Site of metastasis (n, %)

 Bone

41 (82%)

 Lymph node

6 (12%)

 Organ

3 (6%)

Gleason scores (median, range)

8 (range 6–9)

Pre-therapeutic PSA (ng/ml) (median, range)

50 (8–1201)

Nadir PSA (ng/ml) (median)

1.1 (0.02–50)

Time to nadir PSA (month) (mean ± SD, range)

3.85 ± 1.6 (1–7)

Cores involved (mean ± SD, range)

5.39 ± 3.11 (1–11)

Percentage of cores involved (mean ± SD, range)

67.12 ± 27.14 (4–100)

PSA at last follow-up (ng/ml) (median, range)

1.95 (0.02–85)

  1. PSA prostate-specific antigens, n number of patients, SD standard deviation